Registered title, quoted from ClinicalTrials.gov
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Shanxi Bethune Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06850285, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
15 years to 80 years; sex: all
Registered eligibility fields
Received Anti-CD30 Ab therapy within 4 weeks before enrollment;
Exclusion criterion 5
Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments;
Exclusion criterion 6
ECOG performance status 0-2,KPS>60%;
Inclusion criterion 8
At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria;
Inclusion criterion 4
Hepatitis B(HBsAg、HBsAb、HBeAg、HBeAb、HBcAb),Hepatitis C(Anti-HCV),Anti-HIV Ⅰ/Ⅱ and anti-TP positive(Hepatitis B DNA test is negative except);
Exclusion criterion 3
Pregnant or lactating women, and women who have a pregnancy plan within six months;
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06850285, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age≥15 years and ≤80years,female and male;
- CD30+ lymphocyte malignancies;
- CD30 expression >10% by immunohistochemistry;
- At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria;
- Not suitable for autologous hematopoietic stem cell transplantation or recurrence after autologous hematopoietic stem cell transplantation;
- Not suitable for BV treatment or relapse after BV treatment, and the expression of CD30 was confirmed by histology;
- The estimated survival time ≥3 months;
- ECOG performance status 0-2,KPS>60%;
- Sufficient organ function:ALT,AST≤2.5×ULN,patients with liver invasion can be relaxed to ≤ 5 x ULN;serum total bilirubin<34 μmol/L;creatinine clearance rate>30 mL/min;EF≥40%;No pericardial effusion and obvious arrhythmia;SpO2≥92%;
- ALC ≥0.5×109/L,PLT>30×109/L,Hb>80 g/L and subjects had apheresis venous access and no contraindications for blood cell separation;
- MRI showed no central involvement of lymphoma;
- Patients with fertility must be willing to be able to use reliable contraceptive measures ;
- The subject or legal guardian can understand and voluntarily sign the written informed consent.
Exclusion Criteria:
- Lymphoma-associated hemophagic cell syndrome;
- Pregnant or lactating women, and women who have a pregnancy plan within six months;
- Hepatitis B(HBsAg、HBsAb、HBeAg、HBeAb、HBcAb),Hepatitis C(Anti-HCV),Anti-HIV Ⅰ/Ⅱ and anti-TP positive(Hepatitis B DNA test is negative except);
- Suffered from other malignant tumors, except for for skin basal cell carcinoma, skin squamous cell carcinoma and cervical carcinoma in situ undergoing the radical treatment;
- Received Anti-CD30 Ab therapy within 4 weeks before enrollment;
- Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments;
- Active uncontrolled bleeding or a known bleeding diathesis;
- Autologous hematopoietic stem cell transplantation was performed within 6 weeks;
- Uncontrollable active bacterial or fungal infection;
- Known allergy to the study drug and its components;
- Suffer from active autoimmune diseases that require systemic treatment ;
- Persons with mental or mental illness who cannot cooperate with treatment and efficacy evaluation;
- Participated in other clinical studies within 1 months prior to this study;
- History of allogeneic hematopoietic stem cell transplantation;
- patients with any condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject.
Quoted from ClinicalTrials.gov, NCT06850285, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06850285, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.